BPC-157 vs TB-500 vs GHK-Cu: which one if you can only afford one?

Three recovery peptides get recommended for almost every complaint: BPC-157 for gut and soft tissue, TB-500 for muscle and inflammation, GHK-Cu for skin and collagen. Budget rarely stretches to all three, and there is almost no honest framework floating around for choosing one. Here is what the evidence and the cost math actually say.

The evidence gap between the three

Not all three sit at the same evidence tier, and that alone should move your decision before price does.

• BPC-157: weak evidence. Mostly animal data plus a large volume of anecdotal use. The only real human trials are small Phase 1/2 rectal-enema studies for ulcerative colitis, and only the abstracts were ever published.
• TB-500: weak evidence. Animal data and community reports. No human RCT has established a dosing protocol.
• GHK-Cu: moderate evidence. It has actual human topical studies behind it, which neither of the other two can claim.

On evidence tier alone, GHK-Cu starts ahead, not on hype but on the amount of real human data available.

The number that actually drives cost: total milligrams

Vial price is a distraction. What sets the cost of a full course is how many total milligrams the commonly reported community protocol calls for, and none of these are clinician-set doses. They are self-reported gray-market numbers, not clinical guidance, and any actual dose belongs to a conversation with an independent clinician.

Community-reported TB-500 patterns cluster around one of two shapes: about 750 mcg/day for 20 days (roughly 15 mg total), or about 5 mg twice a week for 5 weeks then once a week for 2 weeks (roughly 60 mg total). No human RCT has validated either pattern. BPC-157 is typically self-logged at 100-200 mcg/day, a number set by vial size and vendor habit, not by data. Over that same 4-8 week window, that adds up to roughly 3-11 mg total, a fraction of what the reported TB-500 pattern needs.

Run that math before you run the price-per-vial comparison. A cheaper-looking TB-500 vial can still add up to a pricier full protocol than BPC-157, because the reported pattern needs so much more of it.

GHK-Cu breaks the math differently. It is commonly used topically, not only injected, which sidesteps vial, syringe, and reconstitution costs. That is a real budget lever the other two do not offer.

Where the real markup sits

Gray-market pricing has less to do with the compound than people assume. One publicly circulated cost breakdown of a comparable peptide (ipamorelin) found the raw molecule landing near €1.50-2 per 2 mg at wholesale, with EU import, payment processing, and shipping adding a few euros more. Retail price still landed at roughly 3-4x that delivered cost. The markup mostly pays for the vendor's own risk of disappearing, not for a better molecule.

That means whichever of the three you pick, the vendor matters more than the compound. Research-use-only gray market sits below licensed compounding pharmacies on trust, and batch identity is unverifiable without independent testing. A cheap vial from an untested seller is not actually the budget option if it is not what the label says.

A framework, not a recommendation

• Evidence tier. If the strength of human data matters most to you, GHK-Cu has the deepest bench of the three.
• Total protocol mg. If soft-tissue repair is the goal and the budget is tight, BPC-157's typical mg-per-course runs well under TB-500's reported pattern.
• Route. Topical GHK-Cu skips injection supplies entirely. Injectable BPC-157 and TB-500 do not.
• Vendor, always. Whatever you land on, verify the COA (certificate of analysis) before you use it, and run it past our how-to-vet guide.

None of this replaces a conversation with an independent clinician about what fits your case. This is a way to compare the three honestly, not a substitute for that conversation.

Both BPC-157 and TB-500 sit on the FDA's PCAC vote in July 2026, the compounding advisory panel deciding the compoundable status of a set of peptides that includes these two, worth watching since it could reshape the legal-path option (compounding pharmacy vs. gray market) for either compound later this year.

If you are stacking rather than picking one, see how to validate a self-designed recovery stack before you lock a schedule. The full Ouros Lab feed tracks new peptide breakdowns as they publish.

FAQ

Is BPC-157, TB-500, or GHK-Cu the best studied?

GHK-Cu has the strongest human evidence of the three, with actual topical human studies behind it. BPC-157 and TB-500 evidence is weak: mostly animal data and large anecdotal use, with only small early-phase human trials for BPC-157.

Does a cheaper vial mean a cheaper protocol?

Not necessarily. What matters is the total milligrams a commonly reported community protocol calls for. TB-500 patterns commonly run 15-60 mg total across a course, while typical BPC-157 dosing adds up to a few milligrams over the same window. A lower price per vial can still mean a higher total cost.

Can I trust a cheap gray-market vial to contain what the label says?

There is no guarantee. Batch identity in the gray market is unverifiable without independent lab testing, and "for research purposes only" is legal cover, not a quality signal. That is a separate question from which compound you pick.

Do BPC-157 and TB-500 have a path to becoming legally prescribable?

Both sit on the FDA's PCAC vote in July 2026, the compounding advisory panel deciding the compoundable status of a set of peptides that includes these two. Where that lands changes the legal-path option (compounding pharmacy vs. gray market) for both compounds, worth tracking regardless of which one you choose.